ATTR-CM

A recent study develops a more efficient model to assess the likelihood of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure (HF), improving early identification and potential treatment for this underrecognized condition. The propensity model developed in the study demonstrated a 71.9% sensitivity and 95.2% specificity in identifying patients with HF who are more...

Recent advances in gene-silencing and gene-editing therapies have demonstrated significant potential in altering the treatment landscape for transthyretin (TTR) amyloidosis, transforming the disease’s perception from universally progressive and fatal to treatable with highly specific and effective therapies. Gene-silencing and gene-editing therapies have led to substantial improvement in outcomes for patients with ATTR polyneuropathy. Small-scale studies...

The initiation of dapagliflozin is well-tolerated in transthyretin amyloid cardiomyopathy patients treated with tafamidis. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are the latest addition to the portfolio of heart failure (HF) treatments. They have improved clinical outcomes in heart failure patients with reduced ejection fraction (HFrEF) and preserved left ventricular ejection fraction (HFpEF). However, their efficacy...

Active calcium deposition is not associated with microcalcification in the cardiac tissue of transthyretin cardiac amyloidosis patients. Cardiac amyloidosis is a pathological condition characterized by the deposition of amyloid, an insoluble protein with abundant β-sheet structures, within the heart, leading to the manifestation of heart failure symptoms. The primary forms of cardiac amyloidosis consist of...

ATTR-CM treatment is difficult, in most cases, but diflunisal is a promising treatment option for wild-type ATTR-CM. Treatment options for transthyretin amyloid cardiomyopathy (ATTR-CM) have historically been either risky or lacking in long-term efficacy. Treating ATTR-CM is, in most cases, significantly improved when it is discovered early, although this poses some unique challenges of its...

Diagnosing ATTR-CM is usually a difficult and potentially dangerous process, but non-invasive novel modalities could significantly reduce the risk. Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative disease characterized by deposits of amyloid fibrils. It tends to have high morbidity, poor treatment outcomes, and high treatment expenditure. Recent advances in therapeutic strategies for ATTR-CM have shown...

ATTR-CM can only be treated in a limited number of ways, and this article analyzes and compares the currently available treatment options. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, debilitating disease with high mortality. ATTR-CM is caused by transthyretin (TTR) amyloid protein build ups in the myocardium and other organs, in most cases the peripheral...

With a minimal incidence of amyloid recurrence in the cardiac allograft, cardiac transplantation is well tolerated, increases functional ability, and lengthens survival in patients with ATTR-CM, according to a 30-year retrospective study. ATTR-CM should be included in the list of transplantation indications. Cardiomyopathy caused by transthyretin amyloidosis cardiomyopathy (ATTR-CM) is progressive and fatal. Patients with...

In patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), tafamidis was associated with a lower rate of CV-related hospitalizations and a shorter stay. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an underdiagnosed disease characterized by deposits of improperly folded transthyretin amyloid fibrils, resulting in end-organ dysfunction. ATTR-CM patients present with symptoms of invasive cardiomyopathy and heart failure necessitating expensive...